Fisher Asset Management LLC Acquires 104,949 Shares of Celldex Therapeutics, Inc. $CLDX

Fisher Asset Management LLC boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 12.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 927,157 shares of the biopharmaceutical company’s stock after buying an additional 104,949 shares during the period. Fisher Asset Management LLC owned approximately 1.40% of Celldex Therapeutics worth $23,986,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Simplify Asset Management Inc. acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth about $2,199,000. Y Intercept Hong Kong Ltd bought a new position in Celldex Therapeutics during the 2nd quarter worth approximately $1,188,000. Corient Private Wealth LLC acquired a new position in Celldex Therapeutics during the second quarter valued at approximately $4,105,000. American Century Companies Inc. grew its holdings in Celldex Therapeutics by 24.7% during the second quarter. American Century Companies Inc. now owns 779,985 shares of the biopharmaceutical company’s stock valued at $15,873,000 after purchasing an additional 154,664 shares during the period. Finally, TFG Asset Management GP Ltd increased its stake in Celldex Therapeutics by 21.1% in the second quarter. TFG Asset Management GP Ltd now owns 316,150 shares of the biopharmaceutical company’s stock valued at $6,434,000 after purchasing an additional 55,150 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CLDX. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Barclays boosted their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group increased their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Monday. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.50.

Celldex Therapeutics Trading Down 3.5%

CLDX stock opened at $28.94 on Wednesday. The stock has a 50-day moving average price of $25.80 and a two-hundred day moving average price of $25.58. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $31.31. The stock has a market cap of $1.93 billion, a PE ratio of -7.44 and a beta of 1.17.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. On average, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.